FIRENZE (ITALPRESS) – The Board of Directors of Menarini appointed Thomas Cueni new Councillor, “by further strengthening the governance of the Group”, reads in a note. Cueni joined the Board of the multinational pharmaceutical company together with President Eric Cornut, CEO Delegata Elcin Barker Ergun, shareholders Lucia and Alberto Giovanni Aleotti and Carlo Colombini.
With nearly forty years of international experience in the pharmaceutical industry, Cueni has held leading roles, including the Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
In these assignments he played a leading role in the development of cross-border initiatives between different sectors to facilitate access to treatment for chronic diseases and contribute to the definition of strategies to address global health challenges such as COVID-19 pandemic. As part of antimicrobial resistance, he founded the AMR Action Fund, a fund of nearly $1 billion to support the development of new antibiotics.
He was also Chairman Founder of the AMR Industry Alliance, one of the largest private sector coalitions engaged in researching sustainable solutions to counter antimicrobial resistance.
“I am proud to make available to the Menarini Group all my experience and commitment – said Cueni – to become part of a dynamic and growing company, which combines scientific excellence, innovation and global health care, is a unique opportunity for me to contribute to what is most at heart: improving the life of patients, wherever they live.”.
“We are very pleased to welcome Thomas Cueni in Menarini – commented Lucia and Alberto Giovanni Aleotti, shareholders and members of the Board of Directors – his extensive experience in leadership roles for global health policies is fully in line with our mission to combine innovation and responsibility to help improve patient welfare. Its appointment represents not only a strengthening of our leadership, but also a fundamental contribution to our ability to face the challenges of a constantly evolving pharmaceutical industry, in an increasingly complex global geopolitical context. We also wish to express our sincere and personal gratitude to Jürg Witmer who has left his post, for the passion, commitment and value of the Board of Directors over the past 13 years.”.
– Menarini press office photos –
(ITALPRESS).
